Outlook Therapeutics, Inc. (OTLK) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Building F
Iselin, NJ 08852
United States of America (the)
Phone
609 619 3990
Sector
Healthcare
Industry
Biotechnology
Employees
23
First IPO Date
June 14, 2016
| Name | Title | Pay | Year Born |
| Robert Charles Jahr | President, Chief Executive Officer & Director | 603,062 | 1973 |
| Lawrence A. Kenyon | EVice President, Chief Financial Officer, Treasurer, Secretary & Director | 476,170 | 1966 |
| Surendra Sharma | Senior Vice President of Medical Affairs | 0 | N/A |
| Joel Prieve | Senior Vice President of Licensing and M&A | 0 | N/A |
| Jennifer Kissner | Senior Vice President of Clinical Development & Regulatory Affairs | 0 | N/A |
| Jedd Comiskey | Senior Vice President - Head of Europe | 0 | N/A |
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.